This article reviews the relevant biology, efficacy and safety of new medications targeting the
TH17 pathway, including inhibition of IL17 and IL23, particularly in psoriasis and psoriatic …

The discovery of the biological functions of the interleukin-23/-17 axis led to the identification
of IL-23 and IL-17 as important participants in the pathogenesis of several immune-mediated …

Psoriasis is a lingering inflammatory skin disease that attacks the immune system. The
abnormal interactions between T cells, immune cells, and inflammatory cytokines causing …

Psoriatic arthritis (PsA) is a heterogeneous, potentially severe disease. Many therapeutic
agents are now available for PsA, but treatment decisions are not always straightforward. To …

Advancements in the immunopathogenesis of psoriasis have identified interleukin (IL)‐23
and IL‐17 as fundamental contributors in the immune pathways of the disease. Leveraging …

Biologic therapies are parenteral (administered subcutaneously or intravenously) complex
proteins biologically manufactured in mammalian or yeast cell lines that typically function by …

Background Palmoplantar pustular psoriasis (PPPP) is a variant of psoriasis, which has
significant negative impact on quality of life. The cellular and molecular inflammatory …

Abstract Background Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease,
develops in approximately 30% of patients with psoriasis. Previously, chemokine (CXC …

Cytokines such as tumour necrosis factor (TNF)-α, interleukin (IL)-12, interferon (IFN)-γ, IL-
23 and, more recently, IL-9, have been implicated in the initiation/maintenance of …

To assess the efficacy and safety of interleukin (IL)-17A inhibitors in patients with ankylosing
spondylitis (AS). PubMed, EMBASE, and Web of Science were searched up to 5 February …